Loss of glycemic control in type 2 diabetes (T2D) is the outcome of combined defects in insulin action and insulin secretion, both of which have strong genetic and environmental components 1,2 . A major challenge in T2D therapy is to achieve durable glycemic control while minimizing side effects and the risk of hypoglycemia 3 . Small-molecule GKAs are among multiple investigational agents currently under development for their glucose-lowering capacity in T2D 4, 5 . GK (hexokinase IV) is a key component of the mammalian glucose-sensing machinery with tissue-specific roles in insulin secretion by β-cells, glucose utilization and storage in hepatocytes, central glucose sensing and counter-regulatory responses to hypoglycemia 5 . As compared to those of other hexokinase isoforms, unique kinetic properties of GK, such as lack of product inhibition, a high S 0.5 (K m ) value for glucose and positive substrate cooperativity, render it particularly well suited for regulation of blood glucose levels. As such, gain-of-function mutations in GK are central to the molecular pathogenesis of persistent hyperinsulinemic hypoglycemia of infancy, whereas loss-of-function mutations in the enzyme are linked to maturity-onset diabetes of the young type 2 (MODY2) and permanent neonatal diabetes mellitus 5 . Beyond the fundamental relevance of GK in β-cell function, emerging evidence also suggests that increased GK activity and glucose metabolism in these cells can impart mitogenic and prosurvival benefits, thus leading to β-cell mass expansion 6 . Improvement of both β-cell function and mass through increased GK activity may well expand the potential utility of synthetic GKAs beyond T2D to restoration and maintenance of functional β-cell mass for the treatment of type 1 diabetes (T1D).
a r t i c l e s
Loss of glycemic control in type 2 diabetes (T2D) is the outcome of combined defects in insulin action and insulin secretion, both of which have strong genetic and environmental components 1, 2 . A major challenge in T2D therapy is to achieve durable glycemic control while minimizing side effects and the risk of hypoglycemia 3 . Small-molecule GKAs are among multiple investigational agents currently under development for their glucose-lowering capacity in T2D 4, 5 . GK (hexokinase IV) is a key component of the mammalian glucose-sensing machinery with tissue-specific roles in insulin secretion by β-cells, glucose utilization and storage in hepatocytes, central glucose sensing and counter-regulatory responses to hypoglycemia 5 . As compared to those of other hexokinase isoforms, unique kinetic properties of GK, such as lack of product inhibition, a high S 0.5 (K m ) value for glucose and positive substrate cooperativity, render it particularly well suited for regulation of blood glucose levels. As such, gain-of-function mutations in GK are central to the molecular pathogenesis of persistent hyperinsulinemic hypoglycemia of infancy, whereas loss-of-function mutations in the enzyme are linked to maturity-onset diabetes of the young type 2 (MODY2) and permanent neonatal diabetes mellitus 5 . Beyond the fundamental relevance of GK in β-cell function, emerging evidence also suggests that increased GK activity and glucose metabolism in these cells can impart mitogenic and prosurvival benefits, thus leading to β-cell mass expansion 6 . Improvement of both β-cell function and mass through increased GK activity may well expand the potential utility of synthetic GKAs beyond T2D to restoration and maintenance of functional β-cell mass for the treatment of type 1 diabetes (T1D).
All GKAs reported to date bind to the allosteric site in the enzyme, which is located 20 Å from its active site, and markedly increase the affinity of the enzyme for glucose, typically from 7-8 mM to approximately 1-2 mM (refs. 4, 5) . Structural analysis of several GK conformations in the presence and absence of glucose and GKAs has provided insights into the mechanism of its enzymatic action [7] [8] [9] [10] [11] [12] [13] [14] . Although the precise transitions between GK conformations are still under active investigation, several studies indicate that, in the presence of increasing glucose concentrations, GK transitions from an inactive superopen conformation with low affinity for glucose to an active closed conformation that is catalytically competent for binding of substrates and release of products [7] [8] [9] [10] [11] [13] [14] [15] [16] . Gain-of-function mutations in GK, which typically cluster in the allosteric site, and binding of allosteric GKAs to this region cause this transition to occur at lower glucose concentrations 5 . Although several allosteric activators of GK have shown promising short-term effects, a drawback of these compounds is the risk of development of hypoglycemia over time 3, [17] [18] [19] , thus warranting an exploration of alternative pharmacologic modalities for GK activation, particularly of those with a more tempered effect on glucose affinity 5 .
The BCL-2 family protein BAD binds GK and regulates glucose metabolism in the liver and β-cells [20] [21] [22] [23] . BAD belongs to the BH3-only subclass of proapoptotic BCL-2 family proteins, which share sequence homology only within an α-helical BH3 domain. Using mutational studies, mouse models and genetic reconstitution assays, we have shown that BAD phosphorylation on a conserved serine residue within its BH3 domain, Ser155 in mouse BAD corresponding to Ser118 in the human sequence, acts as a molecular switch that enables it to enhance glucose metabolism and support insulin secretion in β-cells 22 . Concomitant with these metabolic benefits, phosphorylation of the BH3 domain blocks BAD's capacity to engage the prosurvival proteins BCL-2, BCL-X L and BCL-W and thereby neutralizes its proapoptotic function 20, 22 . Importantly, BAD phosphorylation is sensitive to glucose, nutritional (fed and fasted) states and hormones or growth factors known to regulate metabolic adaptations to nutritional states, thus suggesting that BAD phosphorylation and its functional cross-talk with GK may serve as a homeostatic sensor of the nutrient milieu (reviewed in ref. 20) .
The BAD BH3 domain is not only required but also sufficient to mimic BAD's ability to influence GK, as evidenced by the capacity of stabilized α-helices of BCL-2 domains (SAHBs) modeled after the phospho-BH3 helix of BAD to activate GK and restore insulin secretion in BAD-deficient islets 22 . However, the region of GK engaged by the BAD BH3 domain and the mechanism of enzyme activation was not known. Hydrocarbon-stapled peptides that recapitulate the natural structure of bioactive helices have proven to be both powerful tools for dissecting signaling pathways and prototype therapeutics for targeting protein interactions 22, [24] [25] [26] . Given the functional link between phospho-BAD BH3 and GK 22 , we set out to investigate the molecular and structural properties of BAD SAHBs as synthetic GKAs. Here, we define the enzymatic and structural characteristics of GK bound to the BAD phospho-BH3 helix and demonstrate previously unanticipated fundamental mechanistic distinctions from allosteric GKAs. Thus, phospho-BAD BH3 mimetics may represent a new class of synthetic GKAs.
RESULTS

The effect of phospho-BAD mimetic compounds on GK kinetics
To determine how the inherent characteristics of GK are altered by phospho-BAD BH3, we synthesized a panel of stapled peptides modeled after the human BAD BH3 domain for use in kinetic assays with recombinant GK. This panel included the phosphomimic BAD SAHB A (S118D) and the nonphosphorylatable BAD SAHB A (S118L) variants (Supplementary Table 1 ). We examined GK activity as a function of the Hill equation in order to evaluate the effect of these stapled peptides on the maximal rate of reaction (V max ), the glucose concentration that allows half-maximal activity (S 0.5 ) and substrate cooperativity reflected by the sigmoidal response to increasing glucose concentration (Hill coefficient, n H ). We also tested the effect of an archetypal allosteric activator of GK, RO0281675 (ref. 9) for comparison.
The kinetic profile of recombinant GK treated with vehicle (DMSO) or RO0281675 showed good agreement with published data 9 ( Table 1) . Treatment with RO0281675 increased the V max , by approximately 40%, and the affinity for glucose, as reflected by a change in S 0.5 from 7.49 ± 0.18 mM to 1.62 ± 0.13 mM, with no significant effect on the Hill coefficient ( Table 1) . Similarly, treatment with BAD SAHB A (S118D) did not change the Hill coefficient but increased the V max by 44%, an increase comparable to that induced by RO0281675 (Fig. 1a and Table 1 ). However, treatment with BAD SAHB A (S118D) resulted in only a minimal change in the S 0.5 for glucose (6.54 ± 0.15 from 7.49 ± 0.18 mM) despite the substantial increase in V max ( Table 1) . This is markedly different from the observed increase in GK affinity for glucose upon treatment with RO0281675 ( Table 1) .
Mutation of Ser118 to leucine (BAD SAHB A (S118L)) blunted the capacity of the BAD BH3 helix to activate GK (Fig. 1a and Table 1 ), results consistent with the notion that phosphorylation of serine at this site is important for GK activation by BAD 22 . To further examine the effect of Ser118 phosphorylation, we also tested the kinetic profile of GK treated with a phospho-BAD BH3 stapled peptide in which the residue corresponding to Ser118 was replaced with a phosphoserine (BAD SAHB A (S118pS)) and found that it activates GK in a similar manner to that of BAD SAHB A (S118D), with minimal effect on glucose affinity or substrate cooperativity ( Table 1) . To our knowledge, this is the first chemical mode of GK activation that has little effect on the S 0.5 of the enzyme for glucose. This predicts a mechanism of GK activation that is markedly different from that of all allosteric GKAs reported to date 9, 10, 12, 14, 15, 17, [27] [28] [29] [30] [31] [32] .
Given the distinct modes of GK activation by RO0281675 and BAD SAHB A (S118D), we next tested their combined effects. Cotreatment with RO0281675 and BAD SAHB A (S118D) produced changes in glucose affinity that were similar to those of RO0281675 treatment alone, thus indicating that BAD SAHB A (S118D) does not interfere with RO0281675 binding to the allosteric site ( Fig. 1b and Table 1 ).
Localization of the phospho-BAD BH3 interaction site on GK
The differences between the modes of GK activation by BAD SAHBs and the allosteric activator RO0281675 predicted distinct binding sites for the two compounds. To identify the interaction site for the phospho-BAD BH3 domain on GK, we generated biotinylated and photoreactive BAD SAHB analogs, further derivatized by phosphorylation at Ser118. This allowed for capture of the covalent BAD SAHB A -GK complex and binding-site analysis by MS/MS sequencing 26, 33 . We placed the photoreactive benzoylphenylalanine (Bpa) moiety near BAD SAHB A (S118D) + GKA 1.35 ± 0.07*** 124 ± 1.54* 1.84 ± 0.07* 5.55 ± 0.41*** n = 4
Kinetic parameters were derived with the Hill equation as described in Online Methods. S 0.5 veh /S 0.5 treat in the fourth column calculates the fold change in glucose affinity resulting from each treatment. Data represent means ± s.e.m. For each kinetic parameter, four simultaneous comparisons were made with one-way ANOVA (Online Methods). *P < 0.05; **P < 0.01; ***P < 0.001 compared with vehicle control (veh). Table 1 shows a summary and n values (3-18 per treatment) for all independent experiments performed similarly. a r t i c l e s npg a r t i c l e s either the N terminus (BAD SAHB A (Y110Bpa S118pS)) or C terminus (BAD SAHB A (S118pS D123R F125Bpa)) of the BAD BH3 domain (Supplementary Table 1) . We further installed a C-terminal tryptic site in BAD SAHB A (S118pS D123R F125Bpa) by D123R mutagenesis in order to ensure that the resultant Bpa-containing BAD peptide fragment would be sufficiently small for optimal MS/MS sequencing, as previously reported 33 . Importantly, these biotinylated and photoreactive stapled peptides retained their functional interaction with GK, as demonstrated by their capacity to increase the V max while minimally affecting the S 0.5 for glucose (Supplementary Table 2) .
Exposure of the BAD SAHB A -GK (2:1) mixtures to UV light led to a cross-linked complex as apparent from biotin western analysis ( Fig. 2a and Supplementary Fig. 1) . Importantly, the presence or absence of glucose did not affect the cross-linking of BAD SAHB A -GK complexes ( Fig. 2a and Supplementary Fig. 1 ). These data predict that the binding site for the phospho-BAD BH3 helix on GK is distinct from the allosteric site, which becomes available only in the presence of glucose 5, 10, 12, 32, 34 .
We next determined the explicit sites of cross-linking by using MS. We affinity-purified BAD SAHB A -GK covalent adducts by streptavidin pulldown and visualized them as Coomassie-stained SDS-PAGE bands migrating slightly higher than did input protein.
After excision and in-gel trypsin digestion, we analyzed the crosslinked adducts by nano-LC-MS/MS 26, 33 . We identified Bpa-crosslinked tryptic fragments by searching the MS data for a variable modification corresponding to the mass of the tryptic GK fragment plus the Bpa-containing BAD SAHB A fragment. We identified the cross-linked amino acids within GK by MS/MS sequencing of the cross-linked peptides and used these MS/MS spectral count frequencies as a measure of the abundance of these modifications (Fig. 2b,c and Supplementary Table 3) . Whereas the phospho-BAD peptide with the Bpa moiety closer to the N terminus (BAD SAHB A (Y110Bpa S118pS)) predominantly cross-linked to GK in the vicinity of M115 (Fig. 2b) , the photoreactive SAHB with Bpa installed near the C terminus (BAD SAHB A (S118pS D123R F125Bpa)) uniquely modified the region of GK containing residues I181 (V181 in human GK), T206 and R333 (Fig. 2c) . In addition, both peptides crosslinked to residues centered around L79 and F150, which lie between the unique interaction sites for each photoreactive BAD SAHB A . Strikingly, mapping of the cross-linked residues onto each of the three previously defined conformational states of GK (PDB 1V4T 10 , 4DCH 12 and 1V4S 10 ) demonstrates engagement of the phospho-BAD BH3 domain near the active site of the enzyme (Fig. 2d,e) . The interaction surface identified by phospho-BAD peptides is distinct from that of any published GKA. Consistently with this conclusion, there was little observed effect on the cross-linking pattern upon co-incubation of RO0281675 and the photoreactive BAD SAHB A compounds (Supplementary Fig. 2 ). These data are also consistent with the absence of glucose dependence in cross-linking (Fig. 2a) as well as with the distinct GK kinetic profiles of RO0281675 as compared to BAD SAHBs ( Table 1) .
In the absence of glucose, GK adopts an inactive super-open conformation (PDB 1V4T 10 ), whereas in the presence of glucose, two distinct active structures have been reported: an active closed structure 10 and a glucose-bound intermediate structure 12 (PDB 1V4S 10 and 4DCH 12 , respectively). On the basis of cross-linking of 10, 12 (Fig. 2d,e) . Furthermore, mapping of the most frequently cross-linked residues for each BAD SAHB A (≥25% threshold) onto each of the three GK structures suggests a discrete orientation for phospho-BAD BH3 at the binding interface (Fig. 3) . In the context of the inactive super-open and the active intermediate conformations, phospho-BAD BH3 appears to almost exclusively engage the small domain, with the N terminus oriented toward M115 and the C terminus toward V181, T206 and R333 (Fig. 3a,b) . In contrast, when mapped to the active closed conformer, the N terminus continues to localize to the M115 region of the small domain, but the C terminus would be capable of engaging only the exposed R333 residue of the large domain (Fig. 3c) . Taken together, these data indicate that the phospho-BAD BH3 helix directly engages GK at a new interaction site that is distinct from that of small-molecule allosteric GKAs, results consistent with the unique modulatory effect of BAD observed on GK enzyme kinetics ( Table 1) .
Effect of the phospho-BAD BH3 helix on human donor islets
We previously have shown that phospho-BAD BH3 stapled peptides can restore the insulin-secretory defect of BAD-deficient mouse islets treated with stimulatory glucose concentrations 22 . However, the capacity of these compounds to further enhance insulin release in the presence of endogenous wild-type BAD has not previously been tested. Importantly, we sought to expand our efficacy testing of phospho-BAD SAHBs to human islets. We treated human islets overnight with 3 µM BAD SAHB A (S118D) or SAHB A (S118L) and assessed insulin release after incubation with basal (1.67 mM) or stimulatory (20 mM) glucose concentrations. At 20 mM glucose, islets pretreated with BAD SAHB A (S118D) showed a marked increase in insulin release, whereas islets pretreated with BAD SAHB A (S118L) secreted comparable levels of insulin to those of vehicle-treated control islets (Fig. 4a) . The distinct capacities of BAD SAHB A (S118D) and SAHB A (S118L) to stimulate insulin secretion paralleled their effects on GK activation (Table 1) . Importantly, pretreatment with BAD SAHB A did not augment insulin secretion at 1.67 mM glucose (Fig. 4a) , a concentration that is insufficient to trigger GK activation. Collectively, these data indicate that direct modulation of GK activity by BAD SAHB A (S118D) augments glucose-stimulated insulin secretion, a specific functional outcome in human islets.
Kinetics of GK mutants treated with phospho-BAD mimetic
The location of the BAD SAHB A binding interface near the active site of GK prompted us to examine whether BAD SAHBs could alter the function of active site GK mutants, perhaps by stabilizing otherwise impaired structures, or whether these mutations might prevent BAD SAHB A binding altogether. GKAs can be expected to promote the protein stability of GK mutants in addition to increasing their activity 34 . We selected two naturally occurring MODY2 mutations located near the active site, M298K and E300K, for analysis [35] [36] [37] [38] [39] . Both mutations render the enzyme highly unstable 8, 39, 40 . Previous reports on the M298K mutation have noted substantial deficiencies in multiple enzymatic parameters 34, 36, 39, 41 . We observed impaired kinetic constants for this mutant, including decreased V max , diminished glucose affinity and a decreased Hill coefficient (Fig. 4b and Table 2 ), in agreement with these reports. Upon treatment with BAD SAHB A (S118D), these three kinetic parameters showed marked improvement, including restoration of V max from 57% to 95% of that of the wild-type enzyme (Fig. 4b and Table 2 ). A similar series of studies using the M298K mutant in the presence of an allosteric GKA Residues selectively cross-linked by BAD SAHB A (Y110Bpa S118pS) and (S118pS D123R F125Bpa) are colored orange and blue, respectively, and residues cross-linked by both photoreactive BAD SAHBs are colored tan. For clarity, all of the associated residues are colored, but not all are labeled. Cross-linked residues common to both peptides are among those listed in Supplementary Table 3 . Glucose is depicted in green, the active site loop in white. Table 2 summarizes all independent experiments performed similarly (four experiments per GK mutant). Glucose (mM) npg a r t i c l e s treatment reported a V max increase from approximately 60% to 79% of that of wild-type 34 . However, the restoration of V max in the presence of BAD SAHB A (S118D) occurred with modest effects on the S 0.5 of this mutant, which changed from approximately 11 mM to nearnormal values of 8 mM ( Table 2 ). This result was considerably different from the drastic lowering of S 0.5 to approximately 1 mM observed upon treatment of M298K with an allosteric GKA 34 . These findings reinforce the mechanistic distinction between allosteric GKAs and SAHB A (S118D) ( Table 1) . The active site mutant E300K has previously been reported to display variable kinetics. Some studies indicate near-normal kinetics 36, 37 , whereas others have documented more-moderate and even severe 8, 38 changes in the kinetic profile. We observed near-normal n H and S 0.5 values but a noticeable decrease in V max (84.3% ± 1.89 that of wild-type GK), results comparable to previous reports by Davis et al. 8 and Kesavan et al. 37 . Moreover, this mutant had low expression levels as previously reported 8, 35, 37, 40 . Addition of BAD SAHB A (S118D) fully restored the V max of this mutant to wild-type levels ( Fig. 4c and Table 2 ). These data suggest that binding of BAD SAHB A (S118D) in the vicinity of the active site stabilizes the M298K and E300K mutant forms of GK, thus markedly improving their enzymatic function.
DISCUSSION
Our biochemical and structural dissection of the interaction between GK and the phospho-BAD BH3 helix demonstrates a new binding region and distinct mode of enzyme activation compared to those of allosteric GKAs. Binding of the BAD BH3 helix near the active site of GK augments V max while preserving the native n H and S 0.5 values. The relevance of this interaction mode is further underscored by the ability of the BAD BH3 helix to restore the function of two independent MODY2 mutations residing near the active site of GK. Direct engagement and activation of GK by the BAD BH3 helix also imparts a functional benefit to human donor islets, thus warranting exploration of BAD BH3 mimetic compounds as a new class of GKAs.
The positive cooperativity of monomeric GK for glucose is central to its role as a glucose sensor. This has been explained at the mechanistic level by the ligand-induced slow transition model 42 or the mnemonic model 10 , which has been further refined as the preexisting equilibrium model 12, 13, 16, 32 , all involving distinct conformations of GK, with different affinities for glucose, that interconvert slowly. Structural information for several GK conformers corroborates the mechanistic properties of the enzyme and the glucose dosedependent conversion between conformations [7] [8] [9] [10] [11] [13] [14] [15] [16] . GK exists in a super-open conformation in low glucose concentrations and transitions to an active closed conformation in the presence of glucose and allosteric activators 10 . A glucose-bound intermediate conformation between the inactive super-open and the active closed conformers of GK was recently described 12 . It has been suggested that the degree to which allosteric activators enlarge the allosteric site may determine the extent to which the active site is closed and the affinity for glucose is increased 12 . The transition from this active intermediate to the active closed form is thought to allow higher-affinity glucose binding at the active site, thus enabling catalytic activity 12 . Given the inherent mobility of GK, it is likely that the spectrum of GK conformations in the presence or absence of glucose and other ligands will continue to expand 11, 12 and provide new information on the mechanism of enzyme action. The BAD BH3 domain is the minimal region required for BAD's capacity to activate GK and stimulate glucose metabolism 22 . Our integrative dissection of the mode of engagement and activation of GK by stapled peptides modeled after the BAD BH3 domain indicates that they directly bind GK in the immediate vicinity of the active site and activate the enzyme through a mechanism that is markedly distinct from that of all known allosteric activators, as evidenced by minimal alterations in the enzyme's affinity for glucose. To our knowledge, BAD BH3 mimetic compounds constitute the first example of synthetic GKAs exhibiting a nonallosteric mode of action.
Cross-linking patterns of the phospho-BAD BH3 helix on GK are largely unaffected by the presence or absence of either glucose or an allosteric GKA, both of which dramatically shift GK conformational equilibrium away from the inactive super-open conformation. MS-based mapping of the amino acids most frequently cross-linked by photoreactive BAD SAHBs onto published GK structures suggests that the conformation of BAD SAHB-bound GK probably resembles a structure similar to the inactive super-open or the active intermediate conformers in which the N terminus of the BAD BH3 domain solely engages the apex of the small domain of GK, and the C terminus binds near the interface between the small and large domains proximal to the glucose-binding site (Fig. 3) . Several reports have proposed multiple intermediate GK conformations on the basis of tryptophan fluorescence 7, 13, 34, 43, 44 , X-ray scattering 12 and NMR spectroscopy 45 . Such conformational dynamics were decreased, but not eliminated, in the presence of high glucose concentrations 45 . Thus, the explicit conformational structure of GK upon BAD BH3-domain engagement may indeed be distinct from the crystal structures published to date. Although the spectrum of GK conformers limits mechanistic interpretation of the activating nature of the BAD BH3 helix bound to GK, our data firmly place the BAD BH3 domain near the active site of the enzyme. As a result of this direct interaction, the BAD BH3 domain may stabilize and enable conformational transitions of GK facilitating catalysis or enhancing release of products. This scenario would be consistent with the functional restoration of the M298K and E300K active site mutants in the presence of BAD SAHB A (S118D).
GK activating mutations predominantly cluster in the allosteric site and lower the S 0.5 of the enzyme 5, 39, 46, 47 . The residues identified in our cross-linking studies tend to be closer to a region between the small and large domains of GK than are any of the residues associated with GK activating mutations reported to date, which largely exist away from the glucose-binding site and the proposed BAD interface. Among residues altered in GK activating mutations, V452 is closest to any of those proposed within the interface between GK and the BAD BH3 helix in the inactive open conformation and active intermediate conformation. However, the kinetic profile of the corresponding activating mutation, V452L, differs greatly from the kinetic profiles we have observed in the presence of BAD SAHBs 34 . In light of these considerations and the results of our binding-site localization studies, Kinetic parameters were derived with the Hill equation. Data represent means ± s.e.m. *P < 0.05; ***P < 0.001 compared with vehicle-treated recombinant human wild-type (WT) GK. † P < 0.05; † † P < 0.01; † † † P < 0.001 compared with vehicle-treated mutant GK by one-way ANOVA. npg a r t i c l e s it appears that the interface between GK and the BAD BH3 helix is independent from the locations of the known GK activating mutations.
To date, all published small-molecule GKAs markedly increase the affinity of the enzyme for glucose 9, 10, 14, 15, 17, 19, 27, 30 . This is similar to kinetic alterations reported for GK activating mutations in persistent hyperinsulinemic hypoglycemia of infancy 5, 39, 46, 47 . Beyond their shared capacity to augment the affinity of GK for glucose, GKAs can have diverse effects on the substrate cooperativity and V max of the enzyme 5 . Several studies examining the short-term effects of allosteric GKAs (less than one week) in human subjects with early T2D have reported promising outcomes, including improved β-cell function, decreased hepatic glucose output and a net lowering of glucose levels in glucose tolerance tests that are consistent with known physiologic roles of GK in the β-cell and in liver 17, 18 . However, a concern with allosteric GKAs is their ability to decrease the glucose threshold for GK activation, thus resulting in marked glucose-lowering capacity and the risk of hypoglycemia, as well as other undesired effects such as increased triglyceride levels 19 . This latter effect is expected upon chronic activation of hepatic GK and the associated stimulation of lipogenesis and increased hepatic fat content [48] [49] [50] . Lower doses of GKAs or combination therapies with other antidiabetic agents may circumvent these undesirable outcomes 5 . Furthermore, studies that tested the long-term effects of certain allosteric GKAs (up to four months) in T2D subjects reported initial improvement of glucose homeostasis with a loss of efficacy over time that is not fully understood 19, 51, 52 . These complications are also relevant if pharmacologic activation of GK is to be used as a potential therapeutic approach for expansion of functional β-cell mass in T1D 6 .
The successes and challenges of allosteric GKAs in T2D therapy have spurred active investigation of other chemical and enzymatic modes of GK activation, including development of different classes of GKAs that preserve the native enzymatic properties of the enzyme, especially its affinity for glucose 5 , or 'partial agonists' that more moderately lower the S 0.5 for glucose 12 . To our knowledge, BAD SAHBs are the first example of a class of synthetic GKAs that raise the V max with minimal effect on the affinity of the enzyme for glucose. This is mediated by engaging the enzyme near its active site, thus revealing a new druggable site on GK. By preserving the natural kinetic properties of GK, compounds modeled after the phospho-BAD BH3 helix may have important therapeutic benefits, in addition to serving as powerful tool compounds for further biophysical, structural and enzymatic dissection of GK and its pathologic mutants.
METHODS
Methods and any associated references are available in the online version of the paper. 
